PLCB2 and lung carcinoma: The expression pattern is reported for the first time as a potential marker in MDS PLCB2, involved in inositol phosphate metabolism, has been narrowly linked to the poor prognosis in patients with hepatocellular carcinoma, lung cancer and mammary carcinoma.25